Drug repositioning for immunotherapy in breast cancer using single-cell analysis

• Published in: NPJ systems biology and applications Vol. 10; no. 1; pp. 37 - 11
• Main Authors: Mohammadi, Elyas, Dashti, Samira, Shafizade, Neda, Jin, Han, Zhang, Cheng, Lam, Simon, Tahmoorespur, Mojtaba, Mardinoglu, Adil, Sekhavati, Mohammad Hadi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.04.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 692/4028/67; Antifungal activity; Antifungal agents; Antiviral activity; Antiviral agents; Antiviral drugs; beta-Defensins; Bioinformatics; Biomedical and Life Sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Chromatin; Computational Biology/Bioinformatics; Computer Appl. in Life Sciences; Deregulation; Down-regulation; Drug Repositioning; Epithelial cells; Female; Humans; Immune response; Immune system; Immunomodulation; Immunosuppressive agents; Immunotherapy; Life Sciences; Major histocompatibility complex; Peptides; Single-Cell Analysis; Systems Biology; Therapeutic targets
• DOI: 10.1038/s41540-024-00359-z
• ISSN: 2056-7189

Immunomodulatory peptides, while exhibiting potential antimicrobial, antifungal, and/or antiviral properties, can play a role in stimulating or suppressing the immune system, especially in pathological conditions like breast cancer (BC). Thus, deregulation of these peptides may serve as an immunotherapeutic strategy to enhance the immune response. In this meta-analysis, we utilized single-cell RNA sequencing data and known therapeutic peptides to investigate the deregulation of these peptides in malignant versus normal human breast epithelial cells. We corroborated our findings at the chromatin level using ATAC-seq. Additionally, we assessed the protein levels in various BC cell lines. Moreover, our in-house drug repositioning approach was employed to identify potential drugs that could positively impact the relapse-free survival of BC patients. Considering significantly deregulated therapeutic peptides and their role in BC pathology, our approach aims to downregulate B2M and SLPI, while upregulating PIGR, DEFB1, LTF, CLU, S100A7, and SCGB2A1 in BC epithelial cells through our drug repositioning pipeline. Leveraging the LINCS L1000 database, we propose BRD-A06641369 for B2M downregulation and ST-4070043 and BRD-K97926541 for SLPI downregulation without negatively affecting the MHC complex as a significantly correlated pathway with these two genes. Furthermore, we have compiled a comprehensive list of drugs for the upregulation of other selected immunomodulatory peptides. Employing an immunotherapeutic approach by integrating our drug repositioning pipeline with single-cell analysis, we proposed potential drugs and drug targets to fortify the immune system against BC.